AstraZeneca Annual Report and 144 Form 20-F Information 2005 NOTES TO THE FINANCIAL STATEMENTS CONTINUED 7 SHARE CAPITAL Allotted, called-up Authorised and fully paid 2005 2005 2004 $m $m $m Issued Ordinary Shares $0.25 each 395 395 411 Unissued Ordinary Shares $0.25 each 205 Redeemable Preference Shares 1 each 50,000 600 395 411 The Redeemable Preference Shares carry limited class voting rights and no dividend rights.
This class of shares is capable of redemption at par at the option of the Company on the giving of seven days written notice to the registered holder of the shares.
The movements in share capital during the year can be summarised as follows: No.
of shares million $m At beginning of year 1,645 411 Issues of shares 41 Re-purchase of shares 68 17 At 31 December 2005 1,581 395 Share re-purchases During the year the Company re-purchased, and subsequently cancelled, 67,650,000 Ordinary Shares at an average price of 2445 pence per share.
The total consideration, including expenses, was $3,001m.
The excess of the consideration over the nominal value has been charged against the profit and loss account reserve.
Share schemes A total of 3,500,109 Ordinary Shares were issued during the year in respect of share schemes.
Details of movements in the number of Ordinary Shares under option are shown in Note 24: details of options granted to Directors are shown in the Directors Remuneration Report.
Shares held by subsidiaries No shares in the Company are held by subsidiaries.
8 STATUTORY AND OTHER INFORMATION There are no employees of the Company 2004 nil.
The directors of the Company were paid by another Group company in 2005 and 2004.
The fee for the audit of the Company is $1,600 2004 $1,600.
The Company has guaranteed the external borrowing of a subsidiary, in the amount of $285m.
